Gaucher Disease Clinical Trials

12 recruiting

Gaucher Disease Trials at a Glance

17 actively recruiting trials for gaucher disease are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Durham, Minneapolis, and Fairfax. Lead sponsors running gaucher disease studies include University of Minnesota, Fundación Española de Hematología y Hemoterapía, and Duke University.

Browse gaucher disease trials by phase

Treatments under study

About Gaucher Disease Clinical Trials

Looking for clinical trials for Gaucher Disease? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gaucher Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gaucher Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

World Data on Ambroxol for Patients With GD and GBA Related PD

Gaucher DiseaseParkinson DiseaseGBA Gene Mutation
Shaare Zedek Medical Center300 enrolled3 locationsNCT04388969
Recruiting
Phase 3

A Gaucher Disease Gene Therapy Trial With FLT201

Gaucher Disease Type 1
Spur Therapeutics45 enrolled3 locationsNCT07223944
Recruiting
Phase 1Phase 2

A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)

Gaucher Disease
Prevail Therapeutics15 enrolled8 locationsNCT05487599
Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency Disease+1 more
Genzyme, a Sanofi Company12,000 enrolled318 locationsNCT00358943
Recruiting

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

Gaucher Disease
University of Minnesota30 enrolled1 locationNCT05843552
Recruiting

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma

Gaucher DiseaseAcid SphingoMyelinase Deficiency
Fundación Española de Hematología y Hemoterapía210 enrolled23 locationsNCT05992532
Recruiting

Longitudinal Study of Neurodegenerative Disorders

Gaucher DiseaseBatten DiseaseLeukodystrophy+24 more
University of Pittsburgh1,500 enrolled1 locationNCT03333200
Recruiting
Phase 1Phase 2

A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease

Gaucher Disease Type 1
Lingyi Biotech Co., Ltd.12 enrolled3 locationsNCT06818838
Recruiting

Institutional Registry of Rare Diseases

ParagangliomaPheochromocytomaAmyloidosis+23 more
Hospital Italiano de Buenos Aires380 enrolled1 locationNCT06573723
Recruiting

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

Gaucher Disease, Type 3
University of Minnesota5 enrolled1 locationNCT05586243
Recruiting

Gaucher Disease Outcome Survey (GOS)

Gaucher Disease
Shire1,257 enrolled1 locationNCT03291223
Recruiting

A Long-term Follow-up Study of Gaucher Disease

Gaucher Disease
Duke University200 enrolled1 locationNCT03190837
Recruiting

The GBA Multimodal Study in Parkinson's Disease

Gaucher DiseaseParkinson DiseaseGBA Gene Mutation
Pacific Parkinson's Research Centre25 enrolled3 locationsNCT04101968
Recruiting

Drug Discovery for Parkinson's With Mutations in the GBA Gene

HealthyGaucher DiseaseParkinson Disease+1 more
New York Stem Cell Foundation Research Institute60 enrolled1 locationNCT05536388
Recruiting

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Myasthenia GravisAmyloidosisAlpha-Thalassemia+14 more
xCures1,000 enrolled1 locationNCT06539169
Recruiting

Gaucherite - A Study to Stratify Gaucher Disease

Gaucher Disease, Type IGaucher Disease, Type III
Cambridge University Hospitals NHS Foundation Trust250 enrolled8 locationsNCT03240653
Recruiting
Early Phase 1

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

Type II Gaucher Disease
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine6 enrolled1 locationNCT06272149